A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Pruritus Following Burn Injury
Latest Information Update: 20 May 2021
At a glance
- Drugs Serlopitant (Primary)
- Indications Pruritus
- Focus Therapeutic Use
- Acronyms AUBURN
- Sponsors VYNE Therapeutics
- 07 Jun 2017 Status changed from recruiting to discontinued due to Business Reasons.
- 01 Dec 2016 New trial record